FOXP3 and Alzheimer disease: Chen et al. also reported that treatment with anti-PD-1 antibodies, previously known to ameliorate AD pathologies in both Aβ-driven and tauopathy AD mouse models [8, 9], heightened the presence of FoxP3+ CD4+ Tregs without changing the frequency of Tauopathy-associated CD8+ T cells [6].